Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Sciences Licenses Methylation Technologies to Qiagen

NEW YORK (GenomeWeb News) – OncoMethylome Sciences has inked a worldwide non-exclusive agreement granting Qiagen rights to use certain of its methylation technologies in future Qiagen products, the Liege, Belgium-based firm said today.
The firms anticipate that these future products will expand, among others, Qiagen’s EpiTect product line. Specifically, the agreement covers OncoMethylome Sciences’ methylation-specific PCR technology.
Qiagen will pay OncoMethylome Sciences an upfront fee plus royalties from future product sales utilizing the technology. Additional terms of the pact were not disclosed.
“MSP is a perfect match with our EpiTect product-line and allows us to further enable scientific progress in the development of diagnostics and therapeutics for cancer,” Achim Ribbe, executive director of corporate business development for Qiagen, said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.